Ali Arshad

564 total citations
27 papers, 286 citations indexed

About

Ali Arshad is a scholar working on Surgery, Oncology and Nutrition and Dietetics. According to data from OpenAlex, Ali Arshad has authored 27 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 9 papers in Oncology and 7 papers in Nutrition and Dietetics. Recurrent topics in Ali Arshad's work include Pancreatic and Hepatic Oncology Research (8 papers), Pancreatitis Pathology and Treatment (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Ali Arshad is often cited by papers focused on Pancreatic and Hepatic Oncology Research (8 papers), Pancreatitis Pathology and Treatment (7 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Ali Arshad collaborates with scholars based in United Kingdom, Italy and India. Ali Arshad's co-authors include Ashley R. Dennison, Matthew S. Metcalfe, James A. Stephenson, William P. Steward, Wen Yuan Chung, D. Al-Leswas, Omer Al‐Taan, Bruno Morgan, John Isherwood and Cristina Pollard and has published in prestigious journals such as SHILAP Revista de lepidopterología, British journal of surgery and British Journal Of Nutrition.

In The Last Decade

Ali Arshad

25 papers receiving 280 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ali Arshad United Kingdom 13 80 71 63 58 54 27 286
Liang Wei China 12 72 0.9× 63 0.9× 27 0.4× 131 2.3× 26 0.5× 36 426
MA Hull United Kingdom 6 76 0.9× 134 1.9× 178 2.8× 118 2.0× 69 1.3× 13 451
Wesam A. Nasif Egypt 12 42 0.5× 28 0.4× 23 0.4× 76 1.3× 79 1.5× 32 367
Denghai Mi China 12 145 1.8× 94 1.3× 63 1.0× 174 3.0× 80 1.5× 35 501
Hwee‐Ming Cheng Malaysia 9 65 0.8× 19 0.3× 44 0.7× 53 0.9× 26 0.5× 32 292
Yutao Diao China 13 51 0.6× 105 1.5× 26 0.4× 187 3.2× 61 1.1× 28 493
H Kasper Germany 9 52 0.7× 21 0.3× 41 0.7× 90 1.6× 89 1.6× 28 303
Xiaolong Tang China 12 105 1.3× 37 0.5× 33 0.5× 101 1.7× 51 0.9× 37 311
Filippo Cellai Italy 11 49 0.6× 61 0.9× 10 0.2× 71 1.2× 32 0.6× 28 286

Countries citing papers authored by Ali Arshad

Since Specialization
Citations

This map shows the geographic impact of Ali Arshad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Arshad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Arshad more than expected).

Fields of papers citing papers by Ali Arshad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ali Arshad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Arshad. The network helps show where Ali Arshad may publish in the future.

Co-authorship network of co-authors of Ali Arshad

This figure shows the co-authorship network connecting the top 25 collaborators of Ali Arshad. A scholar is included among the top collaborators of Ali Arshad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ali Arshad. Ali Arshad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Arshad, Ali, et al.. (2021). Reduction-Sensitive Dextran–Paclitaxel Polymer–Drug Conjugate: Synthesis, Self-Assembly into Nanoparticles, and In Vitro Anticancer Efficacy. Bioconjugate Chemistry. 32(12). 2516–2529. 25 indexed citations
3.
Haider, Tanweer, et al.. (2021). Lung Cancer Services and the COVID-19 Pandemic. Annals of King Edward Medical University. 27(1). 146–149.
4.
Isherwood, John, Ali Arshad, Wen Yuan Chung, et al.. (2020). Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3. Annals of Translational Medicine. 8(5). 172–172. 12 indexed citations
7.
Thomas, Anne, Helena L. Fisk, Ali Arshad, et al.. (2016). Plasma and erythrocyte uptake of omega-3 fatty acids from an intravenous fish oil based lipid emulsion in patients with advanced oesophagogastric cancer. Clinical Nutrition. 36(3). 768–774. 15 indexed citations
8.
Arshad, Ali, et al.. (2015). Potential for Proteomic Approaches in Determining Efficacy Biomarkers Following Administration of Fish Oils Rich in Omega‐3 Fatty Acids. Nutrition in Clinical Practice. 30(3). 363–370. 3 indexed citations
9.
Arshad, Ali, John Isherwood, C. Mann, et al.. (2015). Intravenous ω‐3 Fatty Acids Plus Gemcitabine. Journal of Parenteral and Enteral Nutrition. 41(3). 398–403. 17 indexed citations
10.
Stephenson, James A., Omer Al‐Taan, Ali Arshad, et al.. (2013). The Multifaceted Effects of Omega-3 Polyunsaturated Fatty Acids on the Hallmarks of Cancer. SHILAP Revista de lepidopterología. 2013. 1–13. 46 indexed citations
11.
Stephenson, James A., Omer Al‐Taan, Ali Arshad, et al.. (2013). Unsaturated fatty acids differ between hepatic colorectal metastases and liver tissue without tumour in humans: Results from a randomised controlled trial of intravenous eicosapentaenoic and docosahexaenoic acids. Prostaglandins Leukotrienes and Essential Fatty Acids. 88(6). 405–410. 4 indexed citations
12.
Arshad, Ali, Wen Yuan Chung, John Isherwood, et al.. (2013). Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancer. Clinical Nutrition. 33(5). 895–899. 15 indexed citations
13.
Arshad, Ali, Wen Yuan Chung, John Isherwood, et al.. (2013). Restoration of Mannose‐Binding Lectin Complement Activity Is Associated With Improved Outcome in Patients With Advanced Pancreatic Cancer Treated With Gemcitabine and Intravenous ω‐3 Fish Oil. Journal of Parenteral and Enteral Nutrition. 38(2). 214–219. 13 indexed citations
14.
Al-Leswas, D., Ali Arshad, Wen Yuan Chung, et al.. (2013). PP070-SUN PROGRESSION OF THE EARLY WARNING SCORES (EWS) IN SEVERE ACUTE PANCREATITIS PATIENTS TREATED WITH OMEGA-3 FISH OIL: A RANDOMISED CONTROL TRIAL. Clinical Nutrition. 32. S47–S48. 1 indexed citations
16.
Chung, Wen Yuan, Gianpiero Gravante, D. Al-Leswas, et al.. (2013). The Development of a Multiorgan Ex Vivo Perfused Model: Results With the Porcine Liver‐Kidney Circuit Over 24 Hours. Artificial Organs. 37(5). 457–466. 16 indexed citations
17.
Arshad, Ali, Wen Yuan Chung, William P. Steward, Matthew S. Metcalfe, & Ashley R. Dennison. (2012). Reduction in circulating pro‐angiogenic and pro‐inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega‐3 fish oil. HPB. 15(6). 428–432. 34 indexed citations
18.
Arshad, Ali, D. Al-Leswas, James A. Stephenson, Matthew S. Metcalfe, & Ashley R. Dennison. (2011). Potential applications of fish oils rich in n-3 fatty acids in the palliative treatment of advanced pancreatic cancer. British Journal Of Nutrition. 106(6). 795–800. 21 indexed citations
19.
Arshad, Ali, D. Al-Leswas, Omer Al‐Taan, et al.. (2011). Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer. American Journal of Clinical Oncology. 36(4). 411–414. 23 indexed citations
20.
Arshad, Ali, D. Bilku, D. Al-Leswas, et al.. (2011). PP045-SUN AN OMEGA-3 RICH LIPID INFUSION CAN HELP PREVENT TUMOUR-RELATED WEIGHT LOSS IN PATIENTS WITH ADVANCED PANCREATIC CANCER. Clinical Nutrition Supplements. 6(1). 40–40. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026